Pharmaceutical Aspects of Artificial Nutrition

Artificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home se...

Full description

Bibliographic Details
Main Authors: Emilie Reber, Markus Messerli, Zeno Stanga, Stefan Mühlebach
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/8/11/2017
id doaj-05bc493f91e94ec0b75de8b6988981a6
record_format Article
spelling doaj-05bc493f91e94ec0b75de8b6988981a62020-11-25T01:50:24ZengMDPI AGJournal of Clinical Medicine2077-03832019-11-01811201710.3390/jcm8112017jcm8112017Pharmaceutical Aspects of Artificial NutritionEmilie Reber0Markus Messerli1Zeno Stanga2Stefan Mühlebach3Department for Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern University Hospital and University of Bern, 3010 Bern, SwitzerlandDepartment of Pharmaceutical Sciences, Pharmaceutical Care Research Group, University of Basel, 4050 Basel, SwitzerlandDepartment for Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Bern University Hospital and University of Bern, 3010 Bern, SwitzerlandDepartment of Pharmaceutical Sciences, Division of Clinical Pharmacy & Epidemiology/Hospital Pharmacy, University of Basel, 4050 Basel, SwitzerlandArtificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home setting. EN is administered via nasogastric tube or ostomies while PN usually requires a central venous access for administration, straight into the blood stream. The infused nutrients can then be taken up directly by the different organs. PN is targeted as a single daily portion formulated as an oil-in-water emulsion providing the necessary substrates for the catabolic and anabolic metabolism including macro- and micronutrients and fluids. PN has a complex pharmaceutical composition—all-in-one admixture—and its compounding or ready-to-use preparation. The use of PN is more challenging and more expensive compare to the use of EN, commercially available as ready-to-use formulations. EN and concomitant medication is highly challenging. Upon incorrect handling and administration, PN is associated with potentially severe or even fatal complications, mostly relating to the central venous access (e.g., catheter-related sepsis) or to a metabolic intolerance (e.g., hyperglycemia, refeeding syndrome) because of inappropriate administration. A correct order of admixing, correct dosing, and administration of the artificial is crucial for safety and efficacy; clinical and biochemical monitoring of the patient and treatment regimen adaption are necessary. The high number of reactive solutes allow only limited stability of a ready-to-use PN admixture. The potential for numerous incompatibilities and interactions renders PN admixtures generally unsuitable as drug vehicle. Laboratory compatibility and stability testing and pharmaceutical expertise are a prerequisite to define the PN composition including nutrients or even drugs admixed to define the appropriate and individualized nutrition and medication regimen. The aim of this narrative review is to present the actual state-of-the-art to deliver best quality artificial nutrition with special regard on pharmaceutical aspects such as instabilities, incompatibilities, and concomitant co-medication.https://www.mdpi.com/2077-0383/8/11/2017parenteral nutritionenteral nutritionartificial nutritionall-in-one parenteral admixturecompatibilitystabilitypharmaceutical expertisedrug admixingdrug administration
collection DOAJ
language English
format Article
sources DOAJ
author Emilie Reber
Markus Messerli
Zeno Stanga
Stefan Mühlebach
spellingShingle Emilie Reber
Markus Messerli
Zeno Stanga
Stefan Mühlebach
Pharmaceutical Aspects of Artificial Nutrition
Journal of Clinical Medicine
parenteral nutrition
enteral nutrition
artificial nutrition
all-in-one parenteral admixture
compatibility
stability
pharmaceutical expertise
drug admixing
drug administration
author_facet Emilie Reber
Markus Messerli
Zeno Stanga
Stefan Mühlebach
author_sort Emilie Reber
title Pharmaceutical Aspects of Artificial Nutrition
title_short Pharmaceutical Aspects of Artificial Nutrition
title_full Pharmaceutical Aspects of Artificial Nutrition
title_fullStr Pharmaceutical Aspects of Artificial Nutrition
title_full_unstemmed Pharmaceutical Aspects of Artificial Nutrition
title_sort pharmaceutical aspects of artificial nutrition
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2019-11-01
description Artificial nutrition, including enteral (EN) and parenteral (PN) nutrition, is indicated whenever adequate oral nutrition fails to sufficiently supply the necessary nutrients to the body. It is a convenient, efficacious, safe, and well-tolerated form of clinical nutrition in the hospital and home setting. EN is administered via nasogastric tube or ostomies while PN usually requires a central venous access for administration, straight into the blood stream. The infused nutrients can then be taken up directly by the different organs. PN is targeted as a single daily portion formulated as an oil-in-water emulsion providing the necessary substrates for the catabolic and anabolic metabolism including macro- and micronutrients and fluids. PN has a complex pharmaceutical composition—all-in-one admixture—and its compounding or ready-to-use preparation. The use of PN is more challenging and more expensive compare to the use of EN, commercially available as ready-to-use formulations. EN and concomitant medication is highly challenging. Upon incorrect handling and administration, PN is associated with potentially severe or even fatal complications, mostly relating to the central venous access (e.g., catheter-related sepsis) or to a metabolic intolerance (e.g., hyperglycemia, refeeding syndrome) because of inappropriate administration. A correct order of admixing, correct dosing, and administration of the artificial is crucial for safety and efficacy; clinical and biochemical monitoring of the patient and treatment regimen adaption are necessary. The high number of reactive solutes allow only limited stability of a ready-to-use PN admixture. The potential for numerous incompatibilities and interactions renders PN admixtures generally unsuitable as drug vehicle. Laboratory compatibility and stability testing and pharmaceutical expertise are a prerequisite to define the PN composition including nutrients or even drugs admixed to define the appropriate and individualized nutrition and medication regimen. The aim of this narrative review is to present the actual state-of-the-art to deliver best quality artificial nutrition with special regard on pharmaceutical aspects such as instabilities, incompatibilities, and concomitant co-medication.
topic parenteral nutrition
enteral nutrition
artificial nutrition
all-in-one parenteral admixture
compatibility
stability
pharmaceutical expertise
drug admixing
drug administration
url https://www.mdpi.com/2077-0383/8/11/2017
work_keys_str_mv AT emiliereber pharmaceuticalaspectsofartificialnutrition
AT markusmesserli pharmaceuticalaspectsofartificialnutrition
AT zenostanga pharmaceuticalaspectsofartificialnutrition
AT stefanmuhlebach pharmaceuticalaspectsofartificialnutrition
_version_ 1725002136249434112